Kytopen key facts
as of Oct 2026- Developer of a cell engineering platform designed to offer healthy and functional cells.
- Kytopen is valued at approximately $47.0M as of Oct 2026 (last reported valuation).
- It has raised $52.9M across 5 recorded rounds; the latest was Early Stage VC ($7.1M) in Feb 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, Alexandria Venture Investments, The Engine, MassVentures — 16 tracked in total.
- Kytopen has filed 5 Form Ds with the SEC since 2019, most recently Feb 2025 ($7.1M sold to 13 investors).
- Status: Privately Held (backing).
Kytopen's last reported valuation, Sep 2024. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Kytopen: the Monday email on marks, rounds and moves
Kytopen funding rounds
5 roundsWho backs Kytopen
16+Kytopen valuation
Kytopen's last reported valuation was $47 million in Sep 2024. No priced round, secondary trade or fund mark has surfaced since.
How much has Kytopen raised?
Kytopen has raised $52.9 million across 5 recorded rounds since 2019. The largest was a $7.1 million early-stage round in Feb 2025.
Kytopen has filed 5 Form Ds with the SEC since 2019, most recently in Feb 2025 ($7.1 million sold to 13 investors).
Kytopen investors
16 investors are on record for Kytopen, including US National Science Foundation, National Institutes of Health, Alexandria Venture Investments and The Engine. The early-stage round in Feb 2025 drew 13 investors.
About Kytopen
Developer of a cell engineering platform designed to offer healthy and functional cells. The company's tool uses a fast, scalable, and gentle process that yields quality engineered cells in minutes while maintaining cell health and function, enabling researchers to combine continuous fluid flow with electric fields for efficient delivery of payloads to primary cells.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 26
- Website
- kytopen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.